Daniel F Mckay

US Patent:

20170217986, Aug 3, 2017

Filed:

Mar 2, 2015

Appl. No.:

15/123111

Inventors:

John A. MCCAULEY - West Point PA, US
David Johathan BENNETT - Boston MA, US
Christopher J. BUNGARD - West Point PA, US
Thomas J. GRESHOCK - West Point PA, US
M. Katharine HOLLOWAY - West Point PA, US
Peter D. WILLIAMS - Harleysville PA, US
Christian BEAULIEU - Laval, Quebec, CA
Sheldon CRANE - Ile Perrot, Quebec, CA
Stephanie LESSARD - St-Jean-sur-Richelieu, QC, CA
Daniel MCKAY - Milton MA, US
Carmela MOLINARO - Rahway NJ, US
Oscar Miguel MORADEI - Burlington MA, US
Vijayasaradhi SIVALENKA - Singapore, SG
Vouy Linh TRUONG - Pierrefonds, QC, CA
Satyanarayana TUMMANAPALLI - Singapore, SG
- Kirklan, CA

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Merck Canada Inc. - Kirkland QC

International Classification:

C07D 498/10
A61K 31/5375
C07D 413/12
A61K 31/5377
C07D 417/14
A61K 45/06
C07D 487/04
C07D 471/04
C07D 413/06
C07D 265/36
A61K 31/5386
C07D 265/30
C07D 413/14

Abstract:

The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z, Z, V, V, V, R, R, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

US Patent:

20140200197, Jul 17, 2014

Filed:

Sep 9, 2013

Appl. No.:

14/021930

Inventors:

JOHN A. MCCAULEY - MAPLE GLEN PA, US
CHRISTIAN BEAULIEU - LAVAL, CA
DAVID J. BENNETT - NEW HOPE PA, US
CHRISTOPHER J. BUNGARD - LANSDALE PA, US
RONALD K. CHANG - ORELAND PA, US
SHELDON CRANE - ILE PERROT, CA
THOMAS J. GRESHOCK - COLLEGEVILLE PA, US
LI HAO - SINGAPORE, SG
KATE HOLLOWAY - LANSDALE PA, US
JESSE J. MANIKOWSKI - NORRISTOWN PA, US
DANIEL MCKAY - MILTON MA, US
CARMELA MOLINARO - WEST POINT PA, US
OSCAR MIGUEL MORADEI - KIRKLAND, CA
PHILIPPE G. NANTERMET - LANSDALE PA, US
CHRISTIAN NADEAU - MONTREAL, CA
TUMMANAPALLI SATYANARAYANA - SINGAPORE, SG
WILLIAM SHIPE - CHALFONT PA, US
SANJAY KUMAR SINGH - SINGAPORE, SG
VOUY LINH TRUONG - PIERREFONDS, CA
SIVALENKA VIJAYARADHI - SINGAPORE, SG
PETER D. WILLIAMS - HARLEYSVILLE PA, US
CATHERINE M. WISCOUNT - ALLENTOWN PA, US

International Classification:

C07D 265/30
A61K 45/06
C07D 413/12
A61K 31/695
C07D 413/06
C07D 417/12
C07D 487/04
C07F 7/08
A61K 31/5375
A61K 31/5377

US Classification:

514 63, 544165, 5142375, 544152, 5142315, 544141, 5142355, 544160, 5142378, 544153, 5142338, 544128, 5142352, 544133, 5142368, 544138, 544122, 5142358, 544114, 5142365, 544117, 5142332, 544 69

Abstract:

The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.